HONG KONG – Aware of the challenges that lie ahead in China and the need for further investment to expand, drug, device and medical products distributor Cardinal Health may be looking for ways to divest some of its operations announcing that it has "begun to explore strategic alternatives to support its next stage of growth."
HONG KONG – The prolonged pending time for drug approvals in China that has long been a thorn in the side of drug- and medical device-makers should be drastically cut this year, as regulators take steps to become more efficient and shorten procedures.
HONG KONG – The prolonged pending time for drug approvals in China that has long been a thorn in the side of drug- and medical device-makers should be drastically cut this year, as regulators take steps to become more efficient and shorten procedures.
HONG KONG – Encouraged by new policies to boost drug development, biopharmaceutical companies in China are increasingly investing in innovative drugs overseas that are at late R&D stages and bringing the candidates to the domestic market for further clinical studies.
HONG KONG – Encouraged by new policies to boost drug development, biopharmaceutical companies in China are increasingly investing in innovative drugs overseas that are at late R&D stages and bringing the candidates to the domestic market for further clinical studies.
HONG KONG – China has launched a two-invoice system for drug procurement as part of a change that underscores an ongoing reshuffle of the health care industry in the country. By limiting the number of invoices allowed in the drug distribution chain, the system aims to eliminate middlemen, avoid unnecessary invoicing that may facilitate corruption and increase transparency in drug pricing.
